Markets:

Overview

News

Currencies

International

Treasuries

Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

97.51 +1.02 (+1.06%)

Streaming Delayed Price Updated: 9:36 AM EDT, Apr 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Mirum Pharmaceuticals, Inc. - common stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Mirum Pharmaceuticals to Present at the 2023 UBS Biopharma Conference

November 03, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

November 02, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Earnings Outlook For Mirum Pharmaceuticals ↗

November 01, 2023

Via Benzinga

Mirum Pharmaceuticals to Present New Data at The Liver Meeting®

October 30, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Analyst Ratings for Mirum Pharmaceuticals ↗

October 09, 2023

Via Benzinga

Analyst Ratings for Mirum Pharmaceuticals ↗

September 13, 2023

Via Benzinga

Where Mirum Pharmaceuticals Stands With Analysts ↗

August 21, 2023

Via Benzinga

Mirum Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023

October 27, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023 ↗

October 24, 2023

Via Benzinga

Mirum Pharmaceuticals Announces New PDUFA Date for LIVMARLI for the Treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis

October 17, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

7 Small-Cap Stocks That Get the Nod from Wall Street ↗

October 11, 2023

Although small-cap stocks tend to be extremely risky, these compelling ideas just happen to get the nod from Wall Street analysts.

Via InvestorPlace

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 10, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Presents LIVMARLI Clinical Data and Real-World Evidence at NASPGHAN

October 07, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Announces Positive Phase 3 RESTORE Study Results Evaluating Chenodal in Patients with Cerebrotendinous Xanthomatosis

October 02, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Highlight LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting

September 26, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Why Shares of Travere Therapeutics Are Slumping Thursday ↗

September 21, 2023

A mixed trial could hurt a kidney drug's chances of full approval.

Via The Motley Fool

Mirum Pharmaceuticals to Present at the 2023 Cantor Global Healthcare Conference

September 21, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For September 20, 2023 ↗

September 20, 2023

Via Benzinga

Mirum Pharmaceuticals Announces the Appointment of Eric Bjerkholt as Chief Financial Officer

September 11, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 08, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

September 06, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Around $4M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying ↗

September 06, 2023

Although U.S. stocks closed mostly lower on Tuesday, there were a few notable insider trades.

Via Benzinga

Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics

September 05, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals

September 05, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 10, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

August 03, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 3, 2023

July 27, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum’s LIVMARLI® Now Authorized in Canada for Cholestatic Pruritus in Patients with Alagille Syndrome

July 25, 2023

From Mirum Pharmaceuticals

Via Business Wire

Raymond James Maintains Strong Buy Rating for Mirum Pharmaceuticals: Here's What You Need To Know ↗

July 18, 2023

Via Benzinga

Microsoft To Rally Around 16%? Here Are 10 Other Analyst Forecasts For Tuesday ↗

July 18, 2023

B of A Securities boosted the price target for Camtek Ltd. (NASDAQ: CAMT) from $30 to $50. B of A Securities analyst Vivek Arya upgraded the stock from Neutral to Buy. Camtek shares rose 1.8% to $44.02...

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.